Antibody

4개 · ADC 882 · Antibody 4071 · CGT 2714 · 자동 수집 갱신 권장 · 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved4 programs

데이터 갱신 주기입니다. 갱신 대기 7,666개 보기 · Curated Core는 주간 자동 동기화됩니다.

AntibodyLimited DatastaleBenaroya Research InstitutePhase 2

Panitumumab or Cetuximab (Anti-EGFR, Anti-EGFR (Panitumumab or Cetuximab))

Colorectal Cancer; Cholangiocarcinoma · EGFR

#EGFR#Antibody#Phase2#monoclonal-antibody#ColorectalCancer+2
Trials 1Status Active
AntibodyLimited DatastaleShen FengPhase 2

Cadonilimab+Gem/Cis (Cadonilimab+Gem/Cis)

Intrahepatic Cholangiocarcinoma · Intrahepatic Cholangiocarcinoma

#IntrahepaticCholangiocarcinoma#Antibody#Phase2#monoclonal-antibody#Shen
Trials 1Status Active
AntibodyLimited DatastaleMedivirPhase 2

pembrolizumab (Keytruda, MIV-818, MIV-818 (fostroxacitabine bralpamide) + pembrolizumab, fostroxacitabine bralpamide)

Hepatocellular Carcinoma; Intrahepatic Cholangiocarcinoma · Hepatocellular Carcinoma

#HepatocellularCarcinoma#Antibody#Phase2#monoclonal-antibody#IntrahepaticCholangiocarcinoma+1
Trials 1Status Active
AntibodyLimited DatastaleEastern Hepatobiliary Surgery H…Phase 2

durvalumab (Imfinzi, Pemigatinib and Durvalumab)

Biliary Tract Carcinoma; Cholangiocarcinoma · Biliary Tract Carcinoma

#BiliaryTractCarcinoma#Antibody#Phase2#monoclonal-antibody#Cholangiocarcinoma+1
Trials 1Status Recruiting